TC Scientific Inc.

Published purpose

This collaborative project between AC Pharmaceuticals Co., Ltd. in the city of Guangzhou, Guangdong Province, China and TC Scientific Inc. in Edmonton, Alberta, Canada, is to develop lenalidomide sustained-release tablets for the treatment of myelodysplastic syndromes (MDS). TC Scientific Inc. will develop new synthetic routes for lenalidomide and a production process that will be substantially less expensive to execute. The new process will avoid use of strong oxidizing agents and expensive reagents and will also reduce the generation of toxic waste by using less toxic reagents. Consequently, the overall production process will be more environmentally friendly. AC Pharmaceuticals Co., Ltd will develop lenalidomide sustained-release tablets with high bioavailability.